SARS-CoV-2, a new SARS-related Betacoronavirus first reported in December 2019, quickly spread around the world causing an outbreak that was declared a pandemic in March 2020. We have characterized global and antigen-specific immune responses to SARS-CoV-2 in the context of mild vs. severe COVID-19, vaccination, hybrid immunity, and Long COVID.
- PolyBio Foundation
- Generous philanthropic support by the Van Auken Private Foundation, David Henke, Pamela and Edward Taft, The Roddenberry Foundation, and other donors devoted to COVID-19 research
- Program for Breakthrough Biomedical Research, partly funded by the Sandler Foundation
- Fast Grants for COVID-19 research (#2164 and #2208)
- California National Primate Research Research Center Pilot Research Grant
Neidleman J., Luo X., Frouard J., Xie G., Gill G., Stein E.S., McGregor M., Ma T., George A.F., Kosters A., Greene W.C., Vasquez J., Ghosn E., Lee S.*, Roan N.R.* SARS-CoV-2-specific T cells exhibit phenotypic features reflecting helper function, lack of terminal differentiation, and high proliferative potential. 2020. *co-corresponding. Cell Reports Medicine
Neidleman J., Luo X., George A.F., McGregor M., Yang J., Yun C., Murray V., Gill G., Greene W.C., Vasquez J., Lee S., Ghosn E.,* Lynch K.,* Roan N.R.* Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. 2021. *co-corresponding. Cell Reports.
Ma T., Ryu H., McGregor M., Babcock B., Neidleman J., Xie G., George A.F., Frouard J., Murray V., Gill G., Ghosn E., Newell E., Lee S., Roan N.R. Protracted yet coordinated differentiation of long-lived SARAS-CoV-2-specific CD8+ T cells during COVID-19 convalescence. 2021. Journal of Immunology.
Neidleman J., Luo X., McGregor M., Xie G., Murray V., Greene W.C., Lee S.A.*, Roan N.R.* mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. 2021. *co-corresponding. Elife.
Suryawanshi R.K., Chen I.P., Ma T., Syed A.M., Brazer N., Saldhi P. Simoneau C.R., Ciling A., Khalid M.M., Sreekumar B., Chen P., Kumar G.R., Montano M., Gascon R., Tsou C., Garcia-Knight M.A. Sotomayor-Gonzalez A., Servellita V., Gliwa A., Nguyen J., Silva I., Milbes B., Kojima N., Hess V., Shacreaw M., Lopez L., Brobeck M., Turner F., Soveg F.W., George A.F., Fang X. Maishan M., Matthay M., Morris M.K., Wadword D., Hanson C., Greene W.C., Andino R., Spraggon L., Roan N.R.*, Chiu C.Y.*, Doudna J.A.*, Ott M*. Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. 2022. *co-corresponding. Nature
Yin K, Peluso MJ, Luo X, Thomas R, Shin M, Neidleman J, Andrew A, Young K, Ma T, Hoh R, Anglin K, Huang B, Argueta U, Lopez M, Valdivieso D, Asare K, Deveau T, Munter SE, Ibrahim R, Standker L, Lu S, Golberg SA, Lee SA, Lynch KL, Kelly JD, Martin JN, Munch J, Deeks SG, Henrich TJ*, Roan NR*. Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2. 2023. *co-corresponding. Cover Article, Nature Immunology.